Similar articles

• Amsacrine alone or in combination with 5-azacytidine and etoposide in refractory or relapsed acute non lymphoblastic leukemia (ANLL).

  Carella AM, Santini G, Martinengo M, Nati S, Giordano D, Congiu A, Cerri R, Damasio E, Risso M, Rossi E, et al. Carella AM, et al. Haematologica. 1985 Jan-Feb;70(1):39-43. Haematologica. 1985. PMID: 2408974 Clinical Trial. No abstract available.
• Combination chemotherapy with amsacrine (AMSA) and cyclocytidine in refractory childhood leukemia: preliminary observations of a phase II study.

  Miller LP, Miller DR, Tan CT. Miller LP, et al. Cancer Treat Rep. 1983 May;67(5):439-43. Cancer Treat Rep. 1983. PMID: 6189604 No abstract available.
• Phase I study of VP-16 (etoposide) and amsacrine (AMSA) in the treatment of refractory acute leukemia.

  Letendre L, Hinemann V, Hoagland HC, Kovach JS. Letendre L, et al. Med Pediatr Oncol. 1985;13(4):232-4. doi: 10.1002/mpo.2950130414. Med Pediatr Oncol. 1985. PMID: 3839284
• Current status of amsacrine (AMSA) combination chemotherapy programs in acute leukemia.

  Arlin ZA. Arlin ZA. Cancer Treat Rep. 1983 Nov;67(11):967-70. Cancer Treat Rep. 1983. PMID: 6357436 Review. No abstract available.
• Amsacrine (AMSA)--a clinical review.

  Louie AC, Issell BF. Louie AC, et al. J Clin Oncol. 1985 Apr;3(4):562-92. doi: 10.1200/JCO.1985.3.4.562. J Clin Oncol. 1985. PMID: 3884748 Review. No abstract available.